ARCHIVES

EPO Controversy: ODAC To Review EPO Agents in May; SEC Probes Amgen’s Delay in Study Disclosure.

This article is from The Cancer Letter archive.

Vol. 33 No. 08 | March 2, 2007

Download PDF Visit The Full Archive

Related Articles

Geography Still An Issue For Centers: Durant Asks Is It “Holy Water” or Money

April 26, 1985

PDQ Evaluation to Cost NCI More Than Reported

June 29, 1990

Senate Defeats Attempt To Cut NIH Funds

July 8, 1977

Panel Calls For New Office, Advisory Groups To Oversee NCI’s Translational Research.

June 22, 2007

Bioassay Report Clears EDTA

August 12, 1977

CMS Inserts Unprecedented Conditions Into Medicare Coverage of Lung Screening

November 14, 2014